EXPERIENCE OF USE OF NEOADJUVANT DOSE-INTENSIVE CHEMOTHERAPY WITH DOXORUBICIN AND CISPLATIN IN COMBINED TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER: PROSPECTIVE SINGLE-CENTER NON-RANDOMIZED CONTROLLED STUDY

O. A Smirnova; Смирнова О. А; N. E Bondarev; Бондарев Н. Э; A. S Petrova; Петрова А. С; K. D Guseinov; Гусейнов К. Д; N. A Mikaya; Микая Н. А; A. S Artemyeva; Артемьева А. С; T. V Gorodnova; Городнова Т. В; E. A Nekrasova; Некрасова Е. А; O. E Lavrynovych; Лавринович О. Е; V. O Bashlyk; Башлык В. О; A. O Nyuganen; Нюганен А. О; A. V Abramova; Абрамова А. В; A. A Sidoruk; Сидорук А. А; E. A Ulrikh; Ульрих Е. А; T. Yu Semiglazova; Семиглазова Т. Ю; A. F Urmancheeva; Урманчеева А. Ф; I. V Berlev; Берлев И. В

EXPERIENCE OF USE OF NEOADJUVANT DOSE-INTENSIVE CHEMOTHERAPY WITH DOXORUBICIN AND CISPLATIN IN COMBINED TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER: PROSPECTIVE SINGLE-CENTER NON-RANDOMIZED CONTROLLED STUDY

Authors: Smirnova O.A¹, Bondarev N.E¹, Petrova A.S¹, Guseinov K.D¹, Mikaya N.A¹, Artemyeva A.S¹, Gorodnova T.V¹, Nekrasova E.A¹, Lavrynovych O.E¹, Bashlyk V.O¹, Nyuganen A.O¹, Abramova A.V¹, Sidoruk A.A¹, Ulrikh E.A¹^,2, Semiglazova T.Y.¹^,2, Urmancheeva A.F¹^,2, Berlev I.V¹^,2
Affiliations:
1. N.N. Petrov National Medical Research Center of Oncology
2. North-Western State Medical University n.a. I.I. Mechnikov
Issue: No 6 (2018)
Pages: 66-73
Section: Articles
URL: https://journals.eco-vector.com/2073-4034/article/view/295367
ID: 295367

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Objective: to evaluate the results of the use of dose-intensive neoadjuvant chemotherapy (NACT) with doxorubicin and cisplatin in patients with locally advanced cervical cancer stage IB2-IIB. Methods. In the patients participating in the study, the efficacy and toxi-city of 3 cycles of intravenous dose-intensive NACT according to the AP scheme (cisplatin 75 mg/m2, doxorubicin 35 mg/m2) and subsequent radical surgical intervention in 62 (89%) cases were evaluated. Results. The study involved 70 patients with locally advanced cervical cancer at the age of 27-68 years (mean age, 45 years). Against the background of the treatment, an objective response was received from 58 (83%) patients. Progression of the disease was detected in 6 (8.6%) cases; relapse of the disease was diagnosed in 2 (2.8%) patients. Neoadjuvant therapy allowed to perform radical surgical intervention in 61 (87.1%) patients. The tumor pathomorphological response of various degrees was obtained in 58 (82.8%) cases; complete clinical regression of the tumor was confirmed by a complete pathomorphological response in 5 (7.14%) of these cases. The dose-intensive regimen of chemotherapy did not lead to significant complications at the pharmacological and surgical stages of treatment. Conclusion. Analysis of the study results has showed that dose-intensive NACT is an effective method and can be considered as an alternative to standard treatment of locally advanced cervical cancer.

Keywords

locally advanced cervical cancer, dose-intensive neoadjuvant chemotherapy, cisplatin, pathomorphological response

Full Text

References

Torre L.A., Bray F., Siegel R.L., et al. Global Cancer Statistics, 2012. CA Cancer J. Clin. 2015; 65:87-108.
Peters W.A., Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 2005;23(21):4626-33.
Ульрих Е.А., Тамбиева З.А., Урманчеева А.Ф., Моисеенко В.М. Качество жизни больных раком шейки матки I, II стадий после радикальных методов лечения. Вопросы онкологии. 2007;53(5):717-21.
Rydzewska L., Tierney J., Vale C.L., Symonds P.R. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database System. Rev. 2012;12:CD007406. doi: 10.1002/14651858.CD007406.pub3.
Dueck A.C., Mendoza T., Mitchell S., et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PROCTCAE) JAMA. Oncol. 2015;1(8):1051-59. doi: 10.1001/jamaoncol.2015.2639.
Benedetti-Panici P., Scambia G., Greggi S., et al. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical carcinoma: a pilot study. Obstet. Gynecol. 1988(Pt. 1):344-48.
Benedetti-Panici P., Greggi S., Colombo A., et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J. Clin. Oncol. 2002;20(1):179-88.
Choi Y.S., Sin J.I., Kim J.H., et al. Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer. J. Korean. Med. Sci. 2006;21:683-89.
Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur. J. Cancer. 2003;39(17):2470-86.
U.S. National Library of Medicine. ClinicalTrials.gov. [электронный ресурс] Режим доступа: https:// clinicaltrials.gov/ct2/home.

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

EXPERIENCE OF USE OF NEOADJUVANT DOSE-INTENSIVE CHEMOTHERAPY WITH DOXORUBICIN AND CISPLATIN IN COMBINED TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER: PROSPECTIVE SINGLE-CENTER NON-RANDOMIZED CONTROLLED STUDY

Full Text

Abstract

Keywords

Full Text

About the authors

References

Supplementary files

This website uses cookies